Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 23, 2016
Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantationSofia Cuenca, Maria J Ruiz-Cano, Juan Ramón Gimeno-Blanes, et al.
Revista Espanola De Cardiologia (English Ed.)|May 6, 2022
Endomyocardial biopsy-confirmed myocarditis and inflammatory cardiomyopathy: clinical profile and prognosisFernando Domínguez, Rafael Cobas Paz, Clara Salas Antón, et al.
European Heart Journal|December 19, 2017
Identification of capillary rarefaction using intracoronary wave intensity analysis with resultant prognostic implications for cardiac allograft patientsChristopher J Broyd, Francisco Hernández-Pérez, Javier Segovia, et al.
Free Radical Biology & Medicine|March 19, 2019
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibitionAlberto Cruz-Bermúdez, Raquel Laza-Briviesca, Ramiro J Vicente-Blanco, et al.
Frontiers in Cardiovascular Medicine|February 16, 2024
The cardiomyopathy of cystic fibrosis: a modern form of Keshan diseaseJavier Segovia-Cubero, Lorena Ruiz-Bautista, Luis Maiz-Carro, et al.
Nature Communications|September 26, 2015
A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like familiesOriol Calvete, Paula Martinez, Pablo Garcia-Pavia, et al.
Revista Espanola De Cardiologia (English Ed.)|April 23, 2020
Clinical profile and outcome of cardiac amyloidosis in a Spanish referral centerÁngela López-Sainz, Aitor Hernandez-Hernandez, Esther Gonzalez-Lopez, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS studyRoberto Serna-Blasco, Pilar Mediavilla-Medel, Karla Medina, et al.
The Lancet. Oncology|September 27, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialMariano Provencio, Ernest Nadal, Amelia Insa, et al.
Frontiers in Medicine|July 24, 2023
Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfectionsInmaculada Ruiz-Cáceres, Teresa Hermida Romero, Isabel Guerra Merino, et al.
Pageof 7